Here's Why You Should Retain CONMED Stock in Your Portfolio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 07 2024
0mins
Source: NASDAQ.COM
Growth Potential: CONMED Corporation is positioned for growth with a diverse product range and strong recurring revenue from single-use products, despite facing challenges like supply-chain issues and cybersecurity threats.
Financial Performance: The company has experienced a decline in stock value year-to-date but anticipates earnings growth for fiscal 2025, while also facing regulatory scrutiny that could impact its operations.
Analyst Views on CNMD
Wall Street analysts forecast CNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNMD is 53.50 USD with a low forecast of 52.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 42.550
Low
52.00
Averages
53.50
High
55.00
Current: 42.550
Low
52.00
Averages
53.50
High
55.00
About CNMD
CONMED Corporation is a medical technology company, which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
